Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GRI Bio ( (GRI) ) has shared an update.
On November 26, 2025, GRI Bio received a notification from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as per their quarterly report for the period ending September 30, 2025. The company has until January 10, 2026, to submit a compliance plan, which, if accepted, could grant them an extension to regain compliance. The notice does not immediately affect their listing status, but failure to comply could lead to delisting, with an option to appeal if necessary.
The most recent analyst rating on (GRI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
Spark’s Take on GRI Stock
According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.
GRI Bio’s stock is constrained by weak financial performance, with ongoing losses and significant cash burn. Technical indicators and valuation metrics further suggest caution, as the stock trades in a downtrend with negative profitability. The strong equity position provides some support, but overall, the stock is risky with limited appeal under current conditions.
To see Spark’s full report on GRI stock, click here.
More about GRI Bio
Average Trading Volume: 1,215,836
Technical Sentiment Signal: Sell
Current Market Cap: $6.44M
For an in-depth examination of GRI stock, go to TipRanks’ Overview page.